Cargando…
The diffuse large B-cell lymphoma – where do we stand now in everyday clinical practice
BACKGROUND: Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial treatment of...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Versita, Warsaw
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472942/ https://www.ncbi.nlm.nih.gov/pubmed/23077452 http://dx.doi.org/10.2478/v10019-012-0002-6 |